News

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...
Bayer’s Kerendia (finerenone) has been approved by the US Food and Drug Administration (FDA) to treat heart failure (HF) patients with left ventricular ejection fraction (LVEF) of at least 40%.
In a significant move, the U.S. Food and Drug Administration granted approval for Kerendia for patients with heart failure ...
The FDA has broadened the approved use of finerenone (Kerendia) to include treatment for heart failure, according to an ...
US FDA approves Bayer’s finerenone for new indication in patients with heart failure with left ventricular ejection fraction of ≥ 40%: Berlin Wednesday, July 16, 2025, 13:00 H ...
New research explains how low levels of the electrolyte sodium in the blood can disrupt the timing of the heartbeat in ...